Krystal Biotech (FRA:4KB) 6-Month Price Index: 1.34 (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €310.10
GF Value €282.12
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech 6-Month Price Index?

Krystal Biotech FRA:4KB +1.34% 58 6-Month Price Index is 1.34 as of Sep. 03, 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €282.12 (Fairly Valued). The stock has 6 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-03), Krystal Biotech's 6-Month Price Index is 1.34.

Krystal Biotech  (FRA:4KB) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Krystal Biotech 6-Month Price Index Related Terms

FRA:4KB vs AXSM, APGE, IONS: 6-Month Price Index Comparison

For the Biotechnology subindustry, Krystal Biotech's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech  (FRA:4KB) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.34 mean?
Krystal Biotech (FRA:4KB) has a 6-Month Price Index of 1.34 as of Sep. 03, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's 6-Month Price Index too high?
Krystal Biotech's current 6-Month Price Index is 1.34. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's 6-Month Price Index compare to AXSM and APGE?
Krystal Biotech's 6-Month Price Index of 1.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current 6-Month Price Index is 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €282.12, compared to a current price of €310.10 — trading 9.9% above its estimated fair value. The current 6-Month Price Index is 1.34. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current 6-Month Price Index is 1.34 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €310.10 is trading 9.9% above its estimated GF Value™ of €282.12. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for FRA:4KB:

  • 6-Month Price Index: 1.34
  • GF Value™: €282.12 vs. price of €310.10 (9.9% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€310.10
Price
€282.12
GF Value